First generic version of oncology medicine bortezomibe in Brazil
New therapeutic option for patients suffering from multiple myeloma
São Paulo, August 26, 2014 - Sandoz, the generic pharmaceutical division of Novartis, today announces the market introduction in Brazil of the first generic version of oncology medicine bortezomibe.
Sandoz will distribute and promote bortezomibe in Brazil, based on an agreement with Accord Pharmaceuticals. This will be the first Sandoz medicine marketed in Brazil for treatment of hematologic – as opposed to solid – tumors.
Bortezomibe is the first generic version of Janssen-Cilag’s Velcade®. It is indicated for treatment of multiple myelomas, a type of cancer that affects the bone marrow’s plasmatic cells and occurs predominantly in men and women between the age of 50 and 70.
Daiane Trombini, Head of Specialties for Sandoz Brazil, says Sandoz Brazil is already performing strongly in the specialty segment of the market, where the company’s existing portfolio includes a range of oncology injectable and biosimilar medicines aimed at treating complex diseases.
“This is more than a big addition to our portfolio, it will benefit millions of patients. Bortezomibe is not fully reimbursed by the Brazilian government, so the generic version will help to increase access for new patients and provide an additional option for those already undergoing treatment.”
Sandoz is marketing generic bortezomibe in the 3.5 mg lyophilized powder in a vial presentation.
Sandoz, the generic pharmaceuticals division of Novartis, is a global leader in the generic pharmaceutical sector. Sandoz employs over 26,500 employees and its products are available in more than 160 countries, offering a broad range of high-quality, affordable products that are no longer protected by patents. With USD 9.2 billion in sales in 2013, Sandoz has a portfolio of approximately 1,100 molecules, and holds the #1 position globally in biosimilars as well as in generic injectables, ophthalmics, dermatology and antibiotics, complemented by leading positions in the cardiovascular, metabolism, central nervous system, pain, gastrointestinal, respiratory, and hormonal therapeutic areas. Sandoz develops, produces, and markets these medicines, as well as active pharmaceutical and biotechnological substances. Nearly half of Sandoz's portfolio is in differentiated products, which are defined as products that are more difficult to scientifically develop and manufacture than standard generics.
In addition to strong organic growth since consolidating its generics businesses under the Sandoz brand name in 2003, Sandoz has benefitted from strong growth of its acquisitions, which include Lek (Slovenia), Sabex (Canada), Hexal (Germany), Eon Labs (US), EBEWE Pharma (Austria), Oriel Therapeutics (US), and Fougera Pharmaceuticals (US).